|
- Biologics for eosinophilic oesophagitis: a systematic review and meta . . .
The therapeutic efficacy of biologics for EoE and other non-EoE EGIDs is still under debate Therefore, we aim to assess the efficacy and safety of biologics compared to a placebo in the treatment of EoE patients by performing a comprehensive meta-analysis of existing high-quality, double-blind randomized controlled trials (RCTs
- Current state of biologics in treating eosinophilic esophagitis
Eosinophilic esophagitis (EoE) is a chronic, allergen-mediated, eosinophil-predominant, type 2 inflammatory disease that progresses to fibrostenosis of the esophagus if left untreated This review focuses on biologics therapy in EoE and dilation are widely accepted treatment modalities for EoE Biologics have been used as investigational
- Biologics in the Treatment of Eosinophilic Esophagitis: Ready for Use?
Eosinophilic esophagitis (EoE) is a chronic disease mediated by environmental allergens and type 2 immune inflammation, which causes significant symptoms including dysphagia and food impaction 1,2 The incidence and prevalence of EoE are rising and untreated disease can lead to significant esophageal stenosis 2,3 Standard treatments include proton-pump inhibitors (PPIs), swallowed topical
- Biologics in eosinophilic esophagitis - PubMed
Biologics for treatment of EoE may result in symptom and histologic improvement and has the potential to treat disease with minimal side effects Biologics in eosinophilic esophagitis Curr Opin Allergy Clin Immunol 2021 Jun 1;21(3):292-296 doi: 10 1097 ACI 0000000000000741
- Consumer’s Guide to Biologics for Eosinophilic Esophagitis
Some biologics are given intravenously (through a needle into a vein) and some by infusion at a clinic or other setting The biologic approved for EoE is self-administered subcutaneously, into the
- Biologics in Eosinophilic Esophagitis — Ready for Prime Time?
Biologics in Eosinophilic Esophagitis — Ready for Prime Time? Author: Alex Straumann, M D Author Info Affiliations Published December 21, 2022 N Engl J Med 2022; 387: 2379-2380
- DUPIXENT® (dupilumab) For Eosinophilic Esophagitis
Learn more about DUPIXENT® (dupilumab), the first FDA-approved biologic to treat eosinophilic esophagitis (EoE) in adult and pediatric patients aged 1 year and older who weigh at least 33lb (15kg) Serious side effects can occur Please see Important Safety Information and Prescribing Information and Patient Information on website
- Eosinophilic esophagitis: promising therapy, biomarkers, and assessment . . .
Breakthroughs in biologic therapy for eosinophilic esophagitis Biologics and other novel therapies are needed for treatment of EoE because of suboptimal response rates to proton pump inhibitors (PPIs), most topical steroids, and dietary approaches, said Evan S Dellon MD, MPH, professor of medicine at University of North Carolina Chapel Hill
|
|
|